GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
about
Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray StudiesProbing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological EvaluationA Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical CyclizationHighly resistant HIV-1 proteases and strategies for their inhibition.Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studiesGRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.A fission yeast cell-based system for multidrug resistant HIV-1 proteases.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSHot-spot identification on a broad class of proteins and RNA suggest unifying principles of molecular recognition.GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease
P2860
Q27679692-8F7E85E8-8398-4F59-BCE6-9B315601BFE9Q27717366-C39EB7D5-BA52-4CDB-9B0B-DF3C0316FBCAQ27728053-10FC4DA9-FC2A-479A-9E48-2BB1E65443EEQ34082661-88C4711C-670E-451C-B67A-378ED49D8C15Q35386013-49B64F81-CEA9-4162-9C59-A5111CC4A2BBQ35650944-8785B667-A68A-414D-99C5-6B3393C71F91Q35846634-227A37AB-5B50-4649-88A8-F245E027BD14Q35907004-DDFF13A0-087B-4879-BFC3-21C9258DB81CQ36613702-5DB5CB3E-6FCD-4E82-97AC-902A86770FA9Q37335823-E7BCE3DE-C3FC-4E3B-8615-3341EC59A0D9Q37578986-684B0F02-0D58-4A5F-A0C6-87412248BC18Q38708006-79C5BC59-2688-479E-8DA9-4DB8EE676225Q41512122-635B29B6-19B2-4243-B844-DAB669582168Q41930312-7D019600-3EB1-4CDF-A5B5-D805ED458A03Q57063482-DB91B8B1-063F-457C-88FB-A9BDD03F3DE5
P2860
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
GRL-0519, a novel oxatricyclic ...... stant HIV-1 variants in vitro.
@en
type
label
GRL-0519, a novel oxatricyclic ...... stant HIV-1 variants in vitro.
@en
prefLabel
GRL-0519, a novel oxatricyclic ...... stant HIV-1 variants in vitro.
@en
P2093
P2860
P356
P1476
GRL-0519, a novel oxatricyclic ...... istant HIV-1 variants in vitro
@en
P2093
Arun K Ghosh
Chun-Xiao Xu
Debananda Das
Hiroaki Mitsuya
Joseph Richard Campbell
Kalapala Venkateswara Rao
Manabu Aoki
Pedro Miguel Salcedo-Gómez
Yasushi Tojo
P2860
P304
P356
10.1128/AAC.02189-12
P407
P577
2013-02-12T00:00:00Z